3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Lung Neoplasms
20
Ovarian Neoplasms
15
Carcinoma, Non-Small-Cell Lung
15
Fallopian Tube Neoplasms
13
Colorectal Neoplasms
10
Pancreatic Neoplasms
9
Carcinoma, Hepatocellular
9
Melanoma
8
Triple Negative Breast Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Prostatic Neoplasms
5
Neoplasm Metastasis
5
Mycosis Fungoides
5
Lymphoma, T-Cell, Cutaneous
5
Carcinoma, Renal Cell
5
Neoplasms
4
Uterine Cervical Neoplasms
3
Sezary Syndrome
3
Sarcoma
3
Myelodysplastic Syndromes
3
Multiple Myeloma
3
Lymphoma, T-Cell
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Glioblastoma
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Interventions
Methotrexate
21
Ifosfamide
21
Cyclophosphamide
19
Doxorubicin
17
Cisplatin
14
Filgrastim
13
Gemcitabine
12
Etoposide
11
Leucovorin
9
apatinib
8
fludarabine
7
glucarpidase
6
Vincristine
6
Temozolomide
6
Radiotherapy
6
Nivolumab
6
Neoadjuvant Therapy
6
Drug Therapy
6
Carboplatin
6
regorafenib
5
cabozantinib
5
Zoledronic Acid
5
Topotecan
5
Mesna
5
Irinotecan
5
Granulocyte Colony-Stimulating Factor
5
Docetaxel
5
pembrolizumab
4
pegfilgrastim
4
camrelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Osteosarcoma
×
Immunoglobulin G
×
Clear all
NCT04668300
2026-04-15
DOSa
M.D. Anderson Cancer Center
Phase 2
Active not recruiting
75 enrolled